Paddy Mark

TOM of this month goes to ACHIEVE trial (n=2,538), which showed that spironolactone 25 mg daily did not reduce CV events or mortality in dialysis patients, and increased risk of severe hyperkalemia #VA by
@nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.

#blazerwatch plus Adeera Levin #kidneywk #nephsky

oh that's last yr.....

actually 2 in lancet (GBD and Balci)... 😊 #kidneywk

Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinica... In participants with chronic kidney disease at increased risk of disease progression, a fixed dose combination of balcinrenone and dapagliflozin was superior to dapagliflozin alone in reducing albumin...

And another ns-MRA

Balcinrenone added to Dapa in proteinuric CKD

#KidneyWK

@thelancet.com

www.thelancet.com/journals/lan...

Richard Haynes- professor at Oxford, nephrologist. Senior author EMPA-k , 3C etc etc…..

Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023 CKD is a major global health issue, with rising prevalence and increasing importance as a cause of death and as a risk factor for cardiovascular death. A better understating of aetiology, appropriate ...

And the GBD analysis on CKD

From @paddymark.bsky.social and colleagues

www.thelancet.com/journals/lan... in @thelancet.com

#KidneyWk

New Global Burden of Disease report on CKD. Up to 9th leading cause of mortality in adults 😢 #kidneyweek www.thelancet.com/action/showP...

Thanks !!!

Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial Patients undergoing maintenance dialysis for kidney failure are at substantial risk of cardiovascular morbidity and mortality. We aimed to establish i…

Proud to have worked with colleagues and friends around the world on #ACHIEVE. We're disappointed spiro didn't prevent CV death/heart failure hospitalizations, but we've shown it's possible to do publicly funded large RCTs of repurposed meds in ESKD. More to do!
www.sciencedirect.com/science/arti...

Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials Mineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but the…

Following #ACHIEVE our meta-analysis of RCTs of MRAs for pts receiving dialysis in @thelancet.com. Thanks to @lonniepyne.bsky.social for leading. No signal for benefit among low-risk of bias RCTs and a good demo of why we continue to need large simple trials.
www.sciencedirect.com/science/arti...